644 related articles for article (PubMed ID: 20635827)
1. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis.
Olsson S; Pal SN; Stergachis A; Couper M
Drug Saf; 2010 Aug; 33(8):689-703. PubMed ID: 20635827
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.
Kant A; de Vries L; Rolfes L
Drug Saf; 2019 Jan; 42(1):35-43. PubMed ID: 30284215
[TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance in resource-limited countries.
Olsson S; Pal SN; Dodoo A
Expert Rev Clin Pharmacol; 2015; 8(4):449-60. PubMed ID: 26041035
[TBL] [Abstract][Full Text] [Related]
5. A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposals.
Stergachis A; Bartlein RJ; Dodoo A; Nwokike J; Kachur SP
Malar J; 2010 May; 9():148. PubMed ID: 20509971
[TBL] [Abstract][Full Text] [Related]
6. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
7. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization.
Amarasinghe A; Black S; Bonhoeffer J; Carvalho SM; Dodoo A; Eskola J; Larson H; Shin S; Olsson S; Balakrishnan MR; Bellah A; Lambach P; Maure C; Wood D; Zuber P; Akanmori B; Bravo P; Pombo M; Langar H; Pfeifer D; Guichard S; Diorditsa S; Hossain MS; Sato Y
Vaccine; 2013 Apr; 31 Suppl 2():B108-14. PubMed ID: 23598471
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance in the Middle East: a survey of 13 arabic-speaking countries.
Wilbur K
Drug Saf; 2013 Jan; 36(1):25-30. PubMed ID: 23315293
[TBL] [Abstract][Full Text] [Related]
9. Current state of pharmacovigilance in the Arab and Eastern Mediterranean region: results of a 2015 survey.
Qato DM
Int J Pharm Pract; 2018 Jun; 26(3):210-221. PubMed ID: 28737220
[TBL] [Abstract][Full Text] [Related]
10. Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
Graham JE; Borda-Rodriguez A; Huzair F; Zinck E
Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930
[TBL] [Abstract][Full Text] [Related]
11. Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities' Views and Needs.
Matos C; Härmark L; van Hunsel F
Drug Saf; 2016 Nov; 39(11):1105-1116. PubMed ID: 27581398
[TBL] [Abstract][Full Text] [Related]
12. Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring.
Kuemmerle A; Dodoo AN; Olsson S; Van Erps J; Burri C; Lalvani PS
Malar J; 2011 Mar; 10():57. PubMed ID: 21388536
[TBL] [Abstract][Full Text] [Related]
13. Pharmacovigilance activities in ASEAN countries.
Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
[TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance of herbal medicines in Africa: Questionnaire study.
Skalli S; Bencheikh RS
J Ethnopharmacol; 2015 Aug; 171():99-108. PubMed ID: 26027756
[TBL] [Abstract][Full Text] [Related]
15. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study.
Avong YK; Jatau B; Gurumnaan R; Danat N; Okuma J; Usman I; Mordi D; Ukpabi B; Kayode GA; Dutt S; El-Tayeb O; Afolabi B; Ambrose I; Agbaji O; Osakwe A; Ibrahim A; Ogar C; Nosiri H; Avong EB; Adekanmbi V; Uthman O; Abimiku A; Oni YO; Mensah CO; Dakum P; Mberu KE; Ogundahunsi OAT
PLoS One; 2018; 13(8):e0200810. PubMed ID: 30133453
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance in low- and middle-income countries: A review with particular focus on Africa.
Kiguba R; Olsson S; Waitt C
Br J Clin Pharmacol; 2023 Feb; 89(2):491-509. PubMed ID: 34937122
[TBL] [Abstract][Full Text] [Related]
17. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
19. Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries.
Isah AO; Opadeyi AO; Tumwijukye H; Cobelens F; Smith D; Ndomondo-Sigonda M; Harmark L; Tanui P; Tiemersma E; Mmbaga BT; Mahlangu G; Ayinbuomwan SA; Soulaymani R; Pandit JM
Ther Adv Drug Saf; 2023; 14():20420986231188836. PubMed ID: 37529763
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
